Literature DB >> 16569533

The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design.

E Magnus Ohman1, Deepak L Bhatt, P Gabriel Steg, Shinya Goto, Alan T Hirsch, Chiau-Suong Liau, Jean-Louis Mas, Alain-Jean Richard, Joachim Röther, Peter W F Wilson.   

Abstract

BACKGROUND: The risk of atherothrombosis is a large health care burden worldwide. With its global prevalence, there is a need to understand all the associated risk factors, both old and new, and their interdependencies in the development of this complex disease leading to myocardial infarction, ischemic stroke, and vascular death and, thus, the major cause of mortality throughout the world.
METHODS: The REACH Registry sought to compile an international data set to extend our knowledge of atherothrombotic risk factors and ischemic events in the outpatient setting. The Registry will recruit approximately 68,000 outpatients in 44 countries across 6 major regions (Latin America, North America, Europe, Asia, the Middle East, and Australia) from >5000 physician outpatient practices. Patients aged > or =45 years with at least 3 atherothrombotic risk factors or documented cerebrovascular, coronary artery, or peripheral arterial disease will be enrolled. Medical history, risk factors, demographic information, and management will be collected at baseline, and clinical events that occur during the follow-up period of up to 2 years in duration will be recorded.
CONCLUSION: The REACH Registry offers an opportunity to provide a better understanding of the prevalence and clinical consequences of atherothrombosis in the outpatient setting in a wide range of patients from different parts of the world.

Entities:  

Mesh:

Year:  2006        PMID: 16569533     DOI: 10.1016/j.ahj.2005.11.004

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  50 in total

1.  One-year costs associated with cardiovascular disease in Canada: Insights from the REduction of Atherothrombosis for Continued Health (REACH) registry.

Authors:  Kim G Smolderen; Alan Bell; Yang Lei; Eric A Cohen; P Gabriel Steg; Deepak L Bhatt; Elizabeth M Mahoney
Journal:  Can J Cardiol       Date:  2010-10       Impact factor: 5.223

2.  Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure.

Authors:  Emmanuel Sorbets; Julien Labreuche; Tabassome Simon; Laurent Delorme; Nicolas Danchin; Pierre Amarenco; Shinya Goto; Christophe Meune; Kim A Eagle; Deepak L Bhatt; Philippe Gabriel Steg
Journal:  Eur Heart J       Date:  2014-03-09       Impact factor: 29.983

3.  7(th) Asian PAD Workshop.

Authors: 
Journal:  Ann Vasc Dis       Date:  2016-05-25

4.  Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH Registry.

Authors:  Jérémie Abtan; Deepak L Bhatt; Yedid Elbez; Emmanuel Sorbets; Kim Eagle; Yasuo Ikeda; David Wu; Mary E Hanson; Hakima Hannachi; Puneet K Singhal; Philippe Gabriel Steg; Gregory Ducrocq
Journal:  Clin Cardiol       Date:  2016-09-02       Impact factor: 2.882

5.  Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry.

Authors:  Dharam J Kumbhani; Ph Gabriel Steg; Christopher P Cannon; Kim A Eagle; Sidney C Smith; Shinya Goto; E Magnus Ohman; Yedid Elbez; Piyamitr Sritara; Iris Baumgartner; Subhash Banerjee; Mark A Creager; Deepak L Bhatt
Journal:  Eur Heart J       Date:  2014-02-28       Impact factor: 29.983

6.  Associations of renal vascular resistance with albuminuria and other macroangiopathy in type 2 diabetic patients.

Authors:  Kumiko Hamano; Ai Nitta; Takayasu Ohtake; Shuzo Kobayashi
Journal:  Diabetes Care       Date:  2008-06-19       Impact factor: 19.112

7.  Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis.

Authors:  Gregory Ducrocq; Joshua S Wallace; Gabriel Baron; Philippe Ravaud; Mark J Alberts; Peter W F Wilson; Erik Magnus Ohman; Danielle M Brennan; Ralph B D'Agostino; Deepak L Bhatt; Philippe Gabriel Steg
Journal:  Eur Heart J       Date:  2010-02-24       Impact factor: 29.983

8.  Should we screen for masked hypertension in patient with vascular disease?

Authors:  Pascal Delsart; Philippe Marboeuf; Cedric Delhaye; Gilles Lemesle; Claire Mounier-Vehier
Journal:  Vasc Health Risk Manag       Date:  2010-05-25

9.  Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry.

Authors:  Rajendra H Mehta; Deepak L Bhatt; Ph Gabriel Steg; Shinya Goto; Alan T Hirsch; Chiau-Suong Liau; Joachim Röther; Peter W F Wilson; Alain-Jean Richard; Kim A Eagle; E Magnus Ohman
Journal:  Eur Heart J       Date:  2008-11-07       Impact factor: 29.983

10.  Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry.

Authors:  Mark J Alberts; Deepak L Bhatt; Jean-Louis Mas; E Magnus Ohman; Alan T Hirsch; Joachim Röther; Geneviève Salette; Shinya Goto; Sidney C Smith; Chiau-Suong Liau; Peter W F Wilson; Ph Gabriel Steg
Journal:  Eur Heart J       Date:  2009-08-31       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.